CL2022001307A1 - Compuestos antagonistas de receptores de adenosina. - Google Patents
Compuestos antagonistas de receptores de adenosina.Info
- Publication number
- CL2022001307A1 CL2022001307A1 CL2022001307A CL2022001307A CL2022001307A1 CL 2022001307 A1 CL2022001307 A1 CL 2022001307A1 CL 2022001307 A CL2022001307 A CL 2022001307A CL 2022001307 A CL2022001307 A CL 2022001307A CL 2022001307 A1 CL2022001307 A1 CL 2022001307A1
- Authority
- CL
- Chile
- Prior art keywords
- compounds
- compositions
- adenosine receptor
- receptor antagonist
- antagonist compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 6
- 229940121359 adenosine receptor antagonist Drugs 0.000 title 1
- 239000000296 purinergic P1 receptor antagonist Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 4
- 101150007969 ADORA1 gene Proteins 0.000 abstract 2
- 101150051188 Adora2a gene Proteins 0.000 abstract 2
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 108050000203 Adenosine receptors Proteins 0.000 abstract 1
- 102000009346 Adenosine receptors Human genes 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000002619 cancer immunotherapy Methods 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente descripción proporciona compuestos antagonistas del receptor de adenosina (p. ej., receptores A2A y/o A1) y composiciones que incluyen dichos compuestos. La presente descripción también proporciona métodos para usar dichos compuestos y composiciones para modular (p. ej., inhibir o antagonizar) los receptores A2A y/o A1 en un sistema biológico. Los compuestos y composiciones se usan en diversas aplicaciones terapéuticas que incluyen el tratamiento del cáncer y la inmunooncología. Los compuestos y composiciones se usan en diversas aplicaciones terapéuticas que incluyen el tratamiento de enfermedades del sistema nervioso central o neurodegenerativas, tales como la enfermedad de Parkinson.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020190149117A KR20210061202A (ko) | 2019-11-19 | 2019-11-19 | 벤조나이트릴이 치환된 축합 피리미딘 유도체 및 그의 의약 용도 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2022001307A1 true CL2022001307A1 (es) | 2023-03-03 |
Family
ID=75980093
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2022001307A CL2022001307A1 (es) | 2019-11-19 | 2022-05-18 | Compuestos antagonistas de receptores de adenosina. |
Country Status (13)
Country | Link |
---|---|
US (1) | US20230159534A1 (es) |
EP (1) | EP4061817A4 (es) |
JP (1) | JP2023505915A (es) |
KR (2) | KR20210061202A (es) |
CN (2) | CN114829363A (es) |
AU (2) | AU2020386189B2 (es) |
BR (2) | BR112022009487A2 (es) |
CA (1) | CA3158731A1 (es) |
CL (1) | CL2022001307A1 (es) |
IL (1) | IL293107A (es) |
MX (1) | MX2022005976A (es) |
TW (3) | TW202132305A (es) |
WO (3) | WO2021099838A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11806350B2 (en) | 2020-11-19 | 2023-11-07 | Ildong Pharmaceutical Co., Ltd. | Prevention and/or treatment of CNS disorders |
WO2023201267A1 (en) | 2022-04-13 | 2023-10-19 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA971896B (en) * | 1996-03-26 | 1998-09-07 | Du Pont Merck Pharma | Aryloxy-and arythio-fused pyridines and pyrimidines and derivatives |
JP2000507552A (ja) * | 1996-03-26 | 2000-06-20 | デュポン ファーマシューティカルズ カンパニー | アリールオキシおよびアリールチオ縮合ピリジン、アリールオキシおよびアリールチオ縮合ピリミジン、およびそれらの誘導体 |
WO2001002400A1 (fr) * | 1999-07-02 | 2001-01-11 | Eisai Co., Ltd. | Composes imidazole fusionnes et medicaments contre le diabete sucre |
GB0100621D0 (en) * | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical compounds VI |
GB0100623D0 (en) * | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical compounds IV |
RU2318824C2 (ru) | 2001-11-09 | 2008-03-10 | Си Ви Терапьютикс, Инк. | Антагонисты рецептора аденозина a2b, фармацевтическая композиция на их основе и способ их получения |
WO2009086303A2 (en) * | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
GB0906579D0 (en) * | 2009-04-16 | 2009-05-20 | Vernalis R&D Ltd | Pharmaceuticals, compositions and methods of making and using the same |
WO2011050160A1 (en) * | 2009-10-22 | 2011-04-28 | Biogen Idec Ma Inc. | Pharmaceuticals, compositions and methods of making and using the same |
-
2019
- 2019-11-19 KR KR1020190149117A patent/KR20210061202A/ko unknown
-
2020
- 2020-11-19 CN CN202080080922.1A patent/CN114829363A/zh active Pending
- 2020-11-19 MX MX2022005976A patent/MX2022005976A/es unknown
- 2020-11-19 EP EP20890594.3A patent/EP4061817A4/en active Pending
- 2020-11-19 JP JP2022554968A patent/JP2023505915A/ja active Pending
- 2020-11-19 TW TW109140608A patent/TW202132305A/zh unknown
- 2020-11-19 TW TW109140607A patent/TW202132304A/zh unknown
- 2020-11-19 BR BR112022009487A patent/BR112022009487A2/pt unknown
- 2020-11-19 IL IL293107A patent/IL293107A/en unknown
- 2020-11-19 BR BR122023020015-2A patent/BR122023020015A2/pt unknown
- 2020-11-19 CA CA3158731A patent/CA3158731A1/en active Pending
- 2020-11-19 US US17/777,881 patent/US20230159534A1/en active Pending
- 2020-11-19 AU AU2020386189A patent/AU2020386189B2/en active Active
- 2020-11-19 WO PCT/IB2020/000971 patent/WO2021099838A1/en unknown
- 2020-11-19 WO PCT/IB2020/000970 patent/WO2021099837A1/en active Application Filing
- 2020-11-19 CN CN202211456336.XA patent/CN116425756A/zh active Pending
- 2020-11-19 WO PCT/IB2020/000948 patent/WO2021099832A2/en active Application Filing
- 2020-11-19 TW TW112125972A patent/TW202342481A/zh unknown
- 2020-11-19 KR KR1020227020600A patent/KR20220104760A/ko not_active Application Discontinuation
-
2022
- 2022-05-18 CL CL2022001307A patent/CL2022001307A1/es unknown
-
2023
- 2023-05-09 AU AU2023202886A patent/AU2023202886A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2021099837A1 (en) | 2021-05-27 |
WO2021099838A1 (en) | 2021-05-27 |
KR20220104760A (ko) | 2022-07-26 |
WO2021099832A2 (en) | 2021-05-27 |
IL293107A (en) | 2022-07-01 |
MX2022005976A (es) | 2022-08-18 |
BR112022009487A2 (pt) | 2023-02-23 |
TW202132304A (zh) | 2021-09-01 |
TW202342481A (zh) | 2023-11-01 |
EP4061817A4 (en) | 2023-11-01 |
KR20210061202A (ko) | 2021-05-27 |
TW202132305A (zh) | 2021-09-01 |
WO2021099838A9 (en) | 2021-09-30 |
EP4061817A1 (en) | 2022-09-28 |
WO2021099838A8 (en) | 2021-08-12 |
US20230159534A1 (en) | 2023-05-25 |
JP2023505915A (ja) | 2023-02-13 |
WO2021099832A3 (en) | 2021-07-01 |
CN116425756A (zh) | 2023-07-14 |
AU2020386189A1 (en) | 2022-06-02 |
CA3158731A1 (en) | 2021-05-27 |
CN114829363A (zh) | 2022-07-29 |
AU2020386189B2 (en) | 2024-05-16 |
AU2023202886A1 (en) | 2023-05-25 |
BR122023020015A2 (pt) | 2024-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2022001307A1 (es) | Compuestos antagonistas de receptores de adenosina. | |
CL2022003185A1 (es) | Midazopirimidinas y triazolopirimidinas como inhibidores de a2a/a2b ((sol. div. 202002198) | |
PE20200494A1 (es) | Polinucleotidos de aadc para el tratamiento de la enfermedad de parkinson | |
CO2018002060A2 (es) | Compuestos farmacéuticos | |
JOP20190151B1 (ar) | مركبات أمينو - ترايازولو بيريدين واستخدامها في علاج سرطان | |
DOP2018000204A (es) | Moduladores alostéricos de receptores de acetilcolina nicotínicos | |
BR112016025048A2 (pt) | compostos e composições como agonistas do receptor tipo toll7 | |
CL2011001263A1 (es) | Compuestos derivados de pirimidinonas opcionalmente sustituidas; composicion farmaceutica que los comprende; y su uso como inhibidores de fosfodiesterasa 1 (pde1) para el tratamiento de enfermedades que involucran trastornos de la trayectoria intracelular del receptor de dopamina d1 como parkinson, alzheimer, depresion, enfermedad bipolar, hipertension, glaucoma. | |
DOP2018000065A (es) | Derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cáncer | |
UY36126A (es) | ?compuestos de 6,8-dioxabiciclo[3.2.1]octano-2,3-diol sustituidos como agentes de direccionamiento al asgpr?. | |
PH12018502606A1 (en) | Phosphoramidate nucleoside derivatives as anticancer agents | |
CO2018004933A2 (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer | |
BR112017016487A2 (pt) | 7-benzil-4- (2-metilbenzil) -2,4,6,7,8,9-hexahidroimidazo [1,2-a] pirrido [3,4-e] pirimidin-5 (1h) -ona, análogos desta, e sais do mesmo e métodos para sua utilização na terapia | |
DOP2014000039A (es) | Inhibidores de pde10 de pirimidina | |
ECSP099322A (es) | Compuestos químicos | |
GT201400222A (es) | Agentes para tratar trastornos que implican la modulación de receptores de rianodina | |
UY30282A1 (es) | Compuestos quimicos | |
CO2019002523A2 (es) | Inhibidores de dopamina–β–hidroxilasa penetrantes de la barrera hematoencefálica | |
UY37947A (es) | Amidas de imidazopiridina sustituidas y su uso | |
CO2022003457A2 (es) | Triazolopirimidinas como inhibidores de a2a/a2b | |
DOP2021000198A (es) | Compuestos y su uso en el tratamiento del cáncer | |
UY37729A (es) | NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7 | |
CL2021001656A1 (es) | Compuestos de imidazopiridina e imidazopiridina y sus usos. | |
CL2008003362A1 (es) | Compuestos heterociclos derivados de tieno(2,3-d)pirimidinona, con actividad estimuladora del receptor ampa; composicion farmaceutica; y uso de los compuestos en el tratamiento de afecciones siquiatricas tales como esquizofrenia, depresion y trastornos del aprendizaje. | |
ECSP099539A (es) | Derivados de 3-cinolinacarboxamida y su uso para tratar el cáncer |